Satellite Symposia

SSTR-Targeting Theranostics in NETs and Beyond: Milestones and New Frontiers
Learn more about the development and emerging clinical role of 177Lu-edotreotide in the treatment of neuroendocrine tumors, focusing on its scientific origins and current evidence supporting its use in gastroenteropancreatic NETs. Additionally, the session will explore future directions in SSTR-targeted therapies.

SYMPOSIUM HOST:
Prof. Ken Herrmann, M.D., MBA Nuclear Medicine, University Clinic Essen, Essen, Germany

Speakers:
Prof. Vikas Prasad, M.D., PhD Nuclear Medicine, Mallinckrodt Institute of Radiology, St. Louis, USA
From concept to clinic: The Origins of 177LU-Edotreotide in nets

Dr. Rocío García-Carbonero, M.D., PhD Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain
Translating evidence into practise: The role of 177LU-Edotreotide in nets

Prof. Damian Wild, M.D., PhD Nuclear Medicine, University Hospital of Basel, Basel, Switzerland
Exploring the future of the SSTR-Targeting landscape

Moderation:
Prof. Dr. Frederik Giesel, Department of Nuclear Medicine University Hospital Düsseldorf, Germany

Speakers:
Dr. Bastiaan Privé, MD, PhD, Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
PSMA-PET/CT in prostate cancer: an overview of the current landscape and ongoing studie

Dr. Mijin Yun, CEO of New Curem, Seoul, South Corea
Clinical Study Results of [¹⁸F]PSMA-1007 in South Korea: Advancing Approval and Diagnostic Innovation

Dr. Pedro José Lopez, Medical Director Nuclear Medicine, Hospital del Mar, Barcelona, Spain
¹⁸F-PSMA-1007 PET Imaging in Primary Prostate Cancer Staging: Case Insights and Handling Tricky Uptakes

Prof. Dr. Wolfgang Schäfer, Chief Physician of the Clinic for Nuclear Medicine Maria Hilf Clinics, Mönchengladbach, Germany
Detecting Biochemical Recurrence with 18F-PSMA-1007: Insights, Case Studies, and Managing Unspecific Bone Uptakes

Prof. Dr. Tobias Maurer, Urologist at Martini Klinik Hamburg, University Hospital Hamburg Eppendorf, Germany
PSMA PET instead of painful biopsies – can we put the urologists out of business?

Content/Abstracts/Speakers will be mentioned here as soon as confirmed.

Content/Abstracts/Speakers will be mentioned here as soon as confirmed.

Improving outcomes through early identification and intervention in ATTR-CM

5 min: Welcome and introduction
20 min: ATTR amyloidosis: from clinical suspicion to evidence-based intervention
20 min: Nuclear imaging in ATTR-CM: current practice and future directions
15 min: From imaging to intervention: case-based diagnosis and management of ATTR-CM
5 min: Q&A

Meeting Objectives

• Enhance understanding of both wild-type and hereditary ATTR amyloidosis, with a focus on cardiac involvement, clinical presentation, prognosis and the critical importance of early and accurate detection
• Reinforce the role of nuclear imaging in the evaluation of suspected ATTR-CM, emphasizing its place in the diagnostic pathway and the potential for emerging imaging techniques to enhance detection and disease characterization
• Review the supporting evidence for ATTR-CM management based on robust clinical data and real-world outcomes
• Showcase practical, case-based examples that integrate imaging, genetic testing and multidisciplinary collaboration to optimize patient outcomes

Content/Abstracts/Speakers will be mentioned here as soon as confirmed.

Advancing radiotheranostics: precision medicine of today and the path forward
Join us for a focused satellite symposium exploring the evolving role of radiotheranostics in modern patient care. The session will highlight current clinical applications, breakthroughs in targeted diagnostics and therapies, and the strategic steps needed to integrate radiotheranostics into broader precision medicine frameworks. From today’s innovations to tomorrow’s possibilities, discover how this transformative approach is reshaping healthcare.

Chairperson:
Dr. Ilya Gipp, Medical Director, GE HealthCare

Speakers:
Prof. Gustav von Schulthess, Chairman of the Department of Medical Radiology at University Hospital Zurich
Prof. Lisa Rowley, head of nuclear medicine, University Hospital Coventry & Warwickshire
Prof. Diego Cecchin, head of nuclear medicine, Padova University Hospital.

Can Nuclear Medicine and Its Referrers Allow the PSMA PET Access Gaps to Persist?​
Despite its demonstrated clinical benefits PSMA PET is insufficiently accessible. A better NMS-Uro relationship is needed to improve patient care.

Speakers:
Prof Vineet Prakash, UK
Accessibility of PSMA PET, a challenge that has not been overcome yet.

Ass Prof Juan Gomes Rivas, Spain
Extended access to PSMA PET is needed to improve the clinical patient management.

Dr Filmont, France
Experience sharing of a full PSMA PET adoption fostered by strong Uro-NMS relations.

Seeing More: Transforming Care with Molecular Imaging
Molecular imaging (MI) is transforming care by enabling practitioners to see more. Discover how next-generation MI technologies are redefining and advancing precision medicine outcomes. Experts will share their opinions and experience on how high-resolution scanning, low-count high-quality imaging, and advanced quantitative analytics unlock new clinical potential. Join us to gain deeper insights across patient populations through enhanced detection capabilities, and translating the findings into actionable treatment monitoring and optimized therapeutic pathways.

Moderator:
Stewart Young, Lead Research Collaboration Scientist, United Imaging Healthcare Europe

Speakers:
Dr. Thomas Mognetti, MD, Head of Nuclear Medicine Department, Centre Léon Bérard, Lyon, France
Low-dose Imaging – Initial Clinical Experience using uMI Panorama PET/CT

Prof. Dr. Roger Gunn, PhD, Chief Science Officer, Xing Imaging, New Haven, USA
High-resolution Brain PET/CT at Xing Imaging using uNeuroEXPLORER

Dr. Claudio Rossetti, MD, Director of Nuclear Medicine Department, ASST Grande Ospedale Metropolitano Niguarda, Italy
Beyond Static: First Clinical Experience with Dynamic LAFOV PET at Niguarda Milan

Prof. Dr. Frank M. Bengel, MD, Director of Nuclear Medicine Department, Medizinische Hochschule Hannover, Germany
Dynamic by Design – Where do we go with LAFOV PET?

Content/Abstracts/Speakers will be mentioned here as soon as confirmed.

Content/Abstracts/Speakers will be mentioned here as soon as confirmed.